WO2019051733A1 - 一种依托泊苷胶束的制备方法 - Google Patents

一种依托泊苷胶束的制备方法 Download PDF

Info

Publication number
WO2019051733A1
WO2019051733A1 PCT/CN2017/101790 CN2017101790W WO2019051733A1 WO 2019051733 A1 WO2019051733 A1 WO 2019051733A1 CN 2017101790 W CN2017101790 W CN 2017101790W WO 2019051733 A1 WO2019051733 A1 WO 2019051733A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
tpgs
micelle
same
etoposide
Prior art date
Application number
PCT/CN2017/101790
Other languages
English (en)
French (fr)
Inventor
顾崧
Original Assignee
顾崧
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 顾崧 filed Critical 顾崧
Publication of WO2019051733A1 publication Critical patent/WO2019051733A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention particularly relates to a method for preparing etoposide micelles.
  • VP-16 Etoposide
  • the sugar metabolite of podophyllotoxin is a semi-synthetic antitumor drug.
  • VP-16 has a good effect on small cell lung cancer, and the effective remission rate is 40%-85%. It is also effective for other tumors such as acute leukemia, ovarian cancer, testicular tumor, malignant lymphoma. At present, VP-16 injection is commonly used in clinical practice.
  • VP-16 is insoluble in water
  • the injection contains a large amount of anhydrous ethanol, Tween 80 and polyethylene glycol 400 as pharmaceutical excipients, which may cause hypersensitivity reaction.
  • Adverse reactions such as gastrointestinal irritation and hypertension make the injection difficult to be tolerated by patients. Therefore, it is urgent to develop a safe and effective VP-16 injection to reduce the adverse reactions of VP-16 injection.
  • D- ⁇ -tocopherol-polyethylene glycol succinate is a water-soluble natural vitamin E derivative consisting of a hydrophobic vitamin E segment and a hydrophilic polyethylene glycol segment. It can be self-assembled to form micelles, and has been used as a delivery carrier for the hydrophobic antitumor drugs paclitaxel, docetaxel, doxorubicin, and the like. Vitamin E is an essential vitamin for the human body, and polyethylene glycol has been approved by the US FDA for use in the human body. Therefore, TPGS is a safe material; as a drug carrier, adverse reactions caused by other excipients can be avoided.
  • the micelle preparation method is simple and does not use toxic solvents, which can improve the safety of the preparation; at the same time, its special "hydrophilic-hydrophobic" segment constitutes a "core-shell” structure, which makes it have excellent performance for loading hydrophobic drugs. Its nano-scale size ( ⁇ 100nm) and hydrophilic shell make it have long-circulating properties and passively target tumor tissue sites, thereby improving efficacy. Micellar has become a hot spot in current research.
  • the preparation method of the etoposide micelle comprises the following steps: dissolving 3-5 parts of VP-16 and 6-12 parts of TPGS in 20-30 parts of methanol, mixing uniformly, and vacuum-steaming at 30-40 ° C The solvent is removed to obtain a uniform mixed film containing VP-16 and TPGS; 80-90 parts of ultrapure water is added, and shaken in a 90-100 ° C water bath to obtain a clear transparent solution, and the solution is filtered with a microporous membrane. It is obtained by vacuum freeze-drying; each raw material is in parts by weight.
  • VP-16 and 9 parts of TPGS are dissolved in 25 parts of methanol.
  • the solvent is removed by vacuum distillation at 35 °C.
  • the preparation method is shaken in a 95 ° C water bath.
  • the pore size of the microporous membrane is 0.22 ⁇ m.
  • the VP-16-TPGS micelle prepared by the method has a small particle size, has a high drug loading amount and an encapsulation efficiency, and has economic value.
  • the preparation method of the etoposide micelle comprises the following steps: dissolving 4 parts of VP-16 and 9 parts of TPGS in 25 parts of methanol, uniformly mixing, and vacuum-removing the solvent at 35 ° C to obtain a uniform content.
  • Mixed film of VP-16 and TPGS adding 85 parts of ultrapure water, shaking in a 95 ° C water bath to obtain a clear transparent solution, using a 0.22 ⁇ m microporous membrane to filter the solution while hot, freeze-drying is obtained; For parts by weight.
  • the preparation method of the etoposide micelle comprises the following steps: dissolving 3 parts of VP-16 and 6 parts of TPGS in 20 parts of methanol, uniformly mixing, and vacuum-removing the solvent at 30 ° C to obtain a uniform content.
  • Mixed film of VP-16 and TPGS adding 80 parts of ultrapure water, shaking in a 90 ° C water bath to obtain a clear transparent solution, using a 0.22 ⁇ m microporous membrane to filter the solution while hot, freeze-drying is obtained; For parts by weight.
  • the preparation method of the etoposide micelle comprises the following steps: dissolving 5 parts of VP-16 and 12 parts of TPGS in 30 parts of methanol, uniformly mixing, and vacuum-removing the solvent at 40 ° C to obtain a uniform content.
  • Mixed film of VP-16 and TPGS adding 90 parts of ultrapure water, shaking in a 100 ° C water bath to obtain a clear transparent solution, using a 0.22 ⁇ m microporous membrane to filter the solution while hot, and lyophilizing in vacuum; For parts by weight.
  • the VP-16-TPGS micelle prepared by the method has a small particle size, has a high drug loading amount and an encapsulation efficiency, and has economic value.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

提供了一种依托泊苷胶束的制备方法，步骤如下：将3-5份VP-16和6-12份TPGS溶于20-30份甲醇中，混合均匀，30-40℃下抽真空旋蒸除去溶剂，制得均一的含VP-16和TPGS的混合薄膜；加入80-90份超纯水，90-100℃水浴中振摇，制得澄清透明溶液，用微孔滤膜趁热过滤溶液，真空冷冻干燥即得；各原料均为重量份。制得的VP-16-TPGS胶束具有较小的粒径，具有较高的载药量和包封率，具有经济价值。

Description

一种依托泊苷胶束的制备方法 技术领域
本发明具体涉及一种依托泊苷胶束的制备方法。
背景技术
依托泊苷(etoposide，VP-16)，化学名为4-去甲基表鬼臼毒素-9-(4,6-O-(R)亚乙基)-β-D-吡喃葡糖苷，鬼臼毒素的糖代谢产物，是一种半合成的抗肿瘤药物。VP-16对小细胞肺癌具有良好的疗效，有效缓解率达40％～85％；对其他多种肿瘤，如急性白血病、卵巢癌、睾丸肿瘤、恶性淋巴瘤等也有效。目前临床上常用为VP-16注射液，由于VP-16难溶于水，该注射液含有大量的无水乙醇、吐温80、聚乙二醇400作为药用辅料，易引起超敏反应、胃肠道刺激、高血压等不良反应，使得该注射液难以被患者耐受。因而亟需开发一种安全、有效的VP-16注射液，以降低VP-16注射液的不良反应。
D-α-生育酚-聚乙二醇琥珀酸酯(TPGS)是一种水溶性的天然维生素E衍生物，由疏水性的维生素E链段和亲水性的聚乙二醇链段组成，可以自组装形成胶束，已被用作疏水性抗肿瘤药物紫杉醇、多烯紫杉醇、多柔比星等的传递载体。维生素E是人体必需的一种维生素，而聚乙二醇已被美国FDA批准可用人体，因而TPGS是一种安全的材料；作为药物载体时，可避免其他辅料所引起的不良反应。
目前，纳米技术已被广泛应用到药物的传递和肿瘤治疗中。胶束制备方法简单且不使用有毒溶剂，可提高制剂的安全性；同时其特殊的“亲水-疏水”链段构成的“核-壳”结构，使其具有优异的装载疏水性药物的性能；而其纳米级别的尺寸(<100nm)及亲水的外壳，使其具有长循环的特性，并被动靶向于肿瘤组织部位，进而提高疗效。胶束已成为目前研究的热点。
发明内容
本发明的目的在于提供一种依托泊苷胶束的制备方法。
本发明通过下面技术方案实现：
一种依托泊苷胶束的制备方法，包括如下步骤：将3-5份VP-16和6-12份TPGS溶于20-30份甲醇中，混合均匀，30-40℃下抽真空旋蒸除去溶剂，制得均一的含VP-16和TPGS的混合薄膜；加入80-90份超纯水，90-100℃水浴中振摇，制得澄清透明溶液，用微孔滤膜趁热过滤溶液，真空冷冻干燥即得；各原料均为重量份。
优选地，所述的制备方法，将4份VP-16和9份TPGS溶于25份甲醇中。
优选地，所述的制备方法，35℃下抽真空旋蒸除去溶剂。
优选地，所述的制备方法，95℃水浴中振摇。
优选地，所述的制备方法，所述微孔滤膜的孔径为0.22μm。
本发明技术效果：
本方法制得的VP-16-TPGS胶束具有较小的粒径，具有较高的载药量和包封率，具有经济价值。
具体实施方式
下面结合实施例具体介绍本发明的实质性内容。
实施例1
一种依托泊苷胶束的制备方法，包括如下步骤：将4份VP-16和9份TPGS溶于25份甲醇中，混合均匀，35℃下抽真空旋蒸除去溶剂，制得均一的含VP-16和TPGS的混合薄膜；加入85份超纯水，95℃水浴中振摇，制得澄清透明溶液，用0.22μm微孔滤膜趁热过滤溶液，真空冷冻干燥即得；各原料均为重量份。
实施例2
一种依托泊苷胶束的制备方法，包括如下步骤：将3份VP-16和6份TPGS溶于20份甲醇中，混合均匀，30℃下抽真空旋蒸除去溶剂，制得均一的含VP-16和TPGS的混合薄膜；加入80份超纯水，90℃水浴中振摇，制得澄清透明溶液，用0.22μm微孔滤膜趁热过滤溶液，真空冷冻干燥即得；各原料均为重量份。
实施例3
一种依托泊苷胶束的制备方法，包括如下步骤：将5份VP-16和12份TPGS溶于30份甲醇中，混合均匀，40℃下抽真空旋蒸除去溶剂，制得均一的含VP-16和TPGS的混合薄膜；加入90份超纯水，100℃水浴中振摇，制得澄清透明溶液，用0.22μm微孔滤膜趁热过滤溶液，真空冷冻干燥即得；各原料均为重量份。
本方法制得的VP-16-TPGS胶束具有较小的粒径，具有较高的载药量和包封率，具有经济价值。

Claims (5)

  1. 一种依托泊苷胶束的制备方法，其特征在于包括如下步骤：将3-5份VP-16和6-12份TPGS溶于20-30份甲醇中，混合均匀，30-40℃下抽真空旋蒸除去溶剂，制得均一的含VP-16和TPGS的混合薄膜；加入80-90份超纯水，90-100℃水浴中振摇，制得澄清透明溶液，用微孔滤膜趁热过滤溶液，真空冷冻干燥即得；各原料均为重量份。
  2. 根据权利要求1所述的制备方法，其特征在于：将4份VP-16和9份TPGS溶于25份甲醇中。
  3. 根据权利要求1所述的制备方法，其特征在于：35℃下抽真空旋蒸除去溶剂。
  4. 根据权利要求1所述的制备方法，其特征在于：95℃水浴中振摇。
  5. 根据权利要求1所述的制备方法，其特征在于：所述微孔滤膜的孔径为0.22μm。
PCT/CN2017/101790 2017-09-14 2017-09-15 一种依托泊苷胶束的制备方法 WO2019051733A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017108256217 2017-09-14
CN201710825621 2017-09-14

Publications (1)

Publication Number Publication Date
WO2019051733A1 true WO2019051733A1 (zh) 2019-03-21

Family

ID=65722316

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/101790 WO2019051733A1 (zh) 2017-09-14 2017-09-15 一种依托泊苷胶束的制备方法

Country Status (1)

Country Link
WO (1) WO2019051733A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112545988A (zh) * 2020-04-03 2021-03-26 南京农业大学 氢溴酸常山酮-tpgs聚合物胶束及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052826A2 (en) * 2000-01-20 2001-07-26 Supratek Pharma Inc. Novel podophyllotoxin compositions
CN103142479A (zh) * 2013-03-29 2013-06-12 中国药科大学 一种磷脂-维生素e琥珀酸聚乙二醇酯胶束的应用
CN105106117A (zh) * 2015-06-26 2015-12-02 中国医学科学院药用植物研究所 一种槲皮素纳米粒及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052826A2 (en) * 2000-01-20 2001-07-26 Supratek Pharma Inc. Novel podophyllotoxin compositions
CN103142479A (zh) * 2013-03-29 2013-06-12 中国药科大学 一种磷脂-维生素e琥珀酸聚乙二醇酯胶束的应用
CN105106117A (zh) * 2015-06-26 2015-12-02 中国医学科学院药用植物研究所 一种槲皮素纳米粒及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAO, XINNAN ET AL.: "Preparation and Characterization of Etoposide Micelles", CHINESE JOURNAL OF MODERN APPLIED PHARMACY, vol. 34, no. 7, 31 July 2017 (2017-07-31), pages 992 - 996, XP055582704 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112545988A (zh) * 2020-04-03 2021-03-26 南京农业大学 氢溴酸常山酮-tpgs聚合物胶束及其制备方法

Similar Documents

Publication Publication Date Title
CN103006539B (zh) 一种聚合物胶束药物组合物及其制备方法
CN100563646C (zh) 一种奥沙利铂脂质体葡萄糖制剂的制备方法
CN113264906B (zh) 多西他赛二聚体小分子前药及其自组装纳米粒的构建
WO2019127297A1 (zh) 四价铂化合物-双环双键两亲性聚合物前药、其纳米胶束及制备方法和应用
Fang et al. Reprogramming axial ligands facilitates the self-assembly of a platinum (iv) prodrug: overcoming drug resistance and safer in vivo delivery of cisplatin
CN105384920A (zh) 一类含硒或碲的聚合物及其制备方法与应用
CN102885772B (zh) 一种载多烯紫杉醇混合胶束制剂及其制备方法
CN102357075A (zh) 一种多西他赛纳米制剂及其制备方法
Fathi Karkan et al. Cisplatin-loaded superparamagnetic nanoparticles modified with PCL-PEG copolymers as a treatment of A549 lung cancer cells
CN105232459A (zh) 一种复溶自组装的水难溶性药物聚合物胶束组合物及其制备方法
CN104523597A (zh) 一种鬼臼毒素类药物的靶向给药制剂
RU2563997C2 (ru) Наночастицы оксалиплатина и способ их получения
CN101474183B (zh) 靶向性抗肿瘤药氯化两面针碱复合物的制备方法、其产品及含有该产品的注射剂
WO2019051733A1 (zh) 一种依托泊苷胶束的制备方法
CN112156066B (zh) 一种包含胶束的可注射复合水凝胶双载药系统的制备方法
CN104098763B (zh) 一种巯基化泊洛沙姆衍生物载体及其制备方法和应用
CN103622924A (zh) 一种多西他赛脂质体及其制备方法
CN112006986A (zh) 一种维生素e琥珀酸酯聚乙二醇纳米胶束及其制备方法和应用
CN112480289B (zh) 一种共担载阿霉素和铂类药物的核壳结构型壳聚糖基纳米前药及其制备方法和应用
CN103933016B (zh) 一种辣椒碱三元纳米胶束及其制法和用途
CN112957330A (zh) 一种多肽介导的雷公藤内酯醇纳米脂质体及制备方法
CN104352498A (zh) 肿瘤靶向丝裂霉素c和甲氨喋呤的双药制剂及其制备方法
CN105796529A (zh) 一种藤黄酸自组装聚合物纳米粒的制备方法及其应用
CN105232460A (zh) 一种奥沙利铂脂质体冻干粉针剂的制备和应用
KR101466511B1 (ko) 저산소증 관련 질환의 진단 및 치료용 저산소 감응형 나노입자

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17924813

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17924813

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 06.10.2020)

122 Ep: pct application non-entry in european phase

Ref document number: 17924813

Country of ref document: EP

Kind code of ref document: A1